Aprea Therapeutics is a biopharmaceutical company that works on developing and selling cancer therapeutics that concentrate on DNA damage repair pathways. Currently, they are conducting phase 1/2a clinical trials for ATRN-119, an ATR inhibitor administered orally for advanced solid tumor patients. A prea's products pipeline includes ATRN-Backup, ATRN-W1051, and ATRN-DDRi.